SequelSEC

Viking Therapeutics, Inc. VKTX

Pharmaceutical Preparations · CIK 0001607678 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$560.02M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Viking Therapeutics, Inc. (VKTX) reported revenue of $0 and net income of -$534.80M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Viking Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Viking Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$560.02M
Net income-$534.80M
Research & development$509.32M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$50.70M
Selling & marketingUnavailable

Balance

Viking Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$125.75M
Total assets$521.90M
Current assets$517.56M
Total liabilities$113.58M
Current liabilities$109.66M
Total equity incl. NCI$408.32M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$69.01M

Cash flow

Viking Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$418.44M
Capital expendituresUnavailable
Investing cash flow$399.26M
Financing cash flow$111.25M
Net change in cashUnavailable
Stock-based compensation$37.39M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Viking Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio4.72x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VKTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-10-23View SEC filing
10-Q · Filed 2025-07-23View SEC filing
10-Q · Filed 2025-04-24View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.